Project Details
Description
BEC administered - This DTF grant is to provide seed funding for the company Omega-One Therapeutics, established from the CUREator biotechnology incubator grant (see linked record 41258) - The project involves the validation of novel, patentable, anti-inflammatory compounds developed jointly by ANU and Monash University. The overall commercialisation strategy for this program is to complete drug-lead optimisation under the CUREator grant, secure Series A investment for pre-clinical studies, then package an FDA approved Investigational New Drug (IND) ready clinical candidate at a substantial valuation increase for further investment or acquisition. CUREator/DTF funding will position the project to attract the Seed investor. The results of the CUREator / DTF project will significantly improve our position with these groups and potentially others.
Status | Finished |
---|---|
Effective start/end date | 1/08/22 → 1/07/23 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.